Evidence map›Paper›PMID 35511079›Full record

ArticleNucleic acids research2022

Identification and characterization of the WYL BrxR protein and its gene as separable regulatory elements of a BREX phage restriction system.

Yvette A Luyten, Deanna E Hausman, Juliana C Young, Lindsey A Doyle, Kerilyn M Higashi, Natalia C Ubilla-Rodriguez, Abigail R Lambert, Corina S Arroyo, Kevin J Forsberg, Richard D Morgan and 2 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Modified DNA substrate selectivity by GmrSD-family Type IV restriction enzyme BrxU.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yvette A LuytenNew England Biolabs, 240 County Road, Ipswich, MA 01938, USA.
Deanna E HausmanDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109, USA.
Juliana C YoungDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109, USA.
Lindsey A DoyleDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109, USA.
Kerilyn M HigashiDepartment of Biology, Seattle University, 901 12th Avenue, Seattle, WA 98122, USA.
Natalia C Ubilla-RodriguezDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109, USA.
Abigail R LambertDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109, USA.
Corina S ArroyoDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109, USA.
Kevin J ForsbergDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109, USA.
Richard D MorganNew England Biolabs, 240 County Road, Ipswich, MA 01938, USA.
Barry L StoddardDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109, USA.ORCID 0000-0001-5174-7858
Brett K KaiserDepartment of Biology, Seattle University, 901 12th Avenue, Seattle, WA 98122, USA.

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6M
MegaTALS: hyperspecific reagents for targeted gene modification and correctionR01GM105691 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STODDARD, BARRY L. · 2014 to 2022
$2.7M
Pilatus 6mS10OD021832 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI ADAMS, PAUL DAVID · 2016 to 2016
$980k
Characterization of the Bacterial BREX Phage Restriction System - Administrative SupplementR15GM140375 · NIGMS · SEATTLE UNIVERSITY · PI Brett Kian Kaiser · 2021 to 2026
$919k
Howard Hughes Medical InstituteNIGMS NIH HHS P30 GM124169NIGMS NIH HHS R01 GM105691NIGMS NIH HHS R15 GM140375NIH HHS S10 OD021832
6 · The paper itself

Abstract

Bacteriophage exclusion ('BREX') phage restriction systems are found in a wide range of bacteria. Various BREX systems encode unique combinations of proteins that usually include a site-specific methyltransferase; none appear to contain a nuclease. Here we describe the identification and characterization of a Type I BREX system from Acinetobacter and the effect of deleting each BREX ORF on growth, methylation, and restriction. We identified a previously uncharacterized gene in the BREX operon that is dispensable for methylation but involved in restriction. Biochemical and crystallographic analyses of this factor, which we term BrxR ('BREX Regulator'), demonstrate that it forms a homodimer and specifically binds a DNA target site upstream of its transcription start site. Deletion of the BrxR gene causes cell toxicity, reduces restriction, and significantly increases the expression of BrxC. In contrast, the introduction of a premature stop codon into the BrxR gene, or a point mutation blocking its DNA binding ability, has little effect on restriction, implying that the BrxR coding sequence and BrxR protein play independent functional roles. We speculate that elements within the BrxR coding sequence are involved in cis regulation of anti-phage activity, while the BrxR protein itself plays an additional regulatory role, perhaps during horizontal transfer.

Indexed as

Antiviral Restriction FactorsBacteriophagesAcinetobacterDNAMethyltransferasesOperonAntiviral Restriction FactorsDNAMethyltransferases

Identifiers

PMID35511079
PMCPMC9122589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.